Northwest Biotherapeutics Inc (NWBO): Cash & Equivalents
$3.04M
As of 2025-12-31
$595.0K
As of 2026-06-30
-24.1%
3-year compound annual growth
-21.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.04M | +39.8% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $2.17M | +2.3% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $2.13M | -69.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.96M | -54.1% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $15.17M | +51.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $9.98M | n/m | 2022-03-01, Balance as of period end |
| 2019-12-31 | $372.0K | -98.3% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $22.22M | n/m | 2020-03-16, Balance as of period end |
| 2017-12-31 | $117.0K | n/c | 2019-04-02, Balance as of period end |
| 2016-12-31 | $6.19M | -71.6% | 2018-04-17, Balance as of period end |
| 2015-12-31 | $21.81M | +62.9% | 2017-04-17, Balance as of period end |
| 2014-12-31 | $13.39M | -27.6% | 2016-03-16, Balance as of period end |
| 2013-12-31 | $18.50M | +151.8% | 2016-03-16, Balance as of period end |
| 2012-12-31 | $7.35M | n/m | 2014-04-01, Balance as of period end |
| 2011-12-31 | $24.0K | -84.3% | 2014-04-01, Balance as of period end |
| 2010-12-31 | $153.0K | +135.4% | 2012-04-13, Balance as of period end |
| 2009-12-31 | $65.0K | n/a | 2012-04-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $18.62M | +394.9% |
Compare NWBO, CPMD, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗